Joint Formulary & PAD

Delgocitinib - Hand eczema

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Red
Formulations :
  • Cream
Associated Icons :
Restrictions / Comments :
Important

Dermatology specialist teams only.

PAD Profile

ChemicalSubstance :
Delgocitinib
Indication :
Hand eczema
Group Name :
Keywords :
CHE
Brand Names Include :
Anzupgo
Important Information :

FIRE HAZARD-: product contains cetostearyl alcohol. Advise patients not to smoke or go near naked flames because of risk of severe burns

Latest Additions Date From :
13 Feb 2026
Latest Additions Date To :
13 Mar 2026
Guidelines :
Supporting Documents :
2

Committee Recommendations (1)

The Surrey Heartlands Integrated Care System Area Prescribing Committee agreed that delgocitinib for the treatment of Chronic Hand Eczema (CHE) is implemented in line with NICE TA1107.

A RED traffic light status for delgocitinib for CHE was agreed.

Prescribing should be initiated and continued by a specialist clinician. If the patient has already been initiated on this medicine by a specialist clinician, please ensure this is recorded as a ‘Hospital Only Drug’ in the patient’s medication list, in order to be alert to potential side-effects and interactions with other medicines prescribed in primary care

Other Indications

Below are listed other indications that Delgocitinib is used to treat.

  • No records returned.

Other Drugs

Below are listed other drugs that are used to treat Hand eczema.